[The efficacy of tiotropium bromide (spiriva) in the treatment of patients with chronic obstructive pulmonary disease of varying severity: results of the Russian trial].

Aim: To evaluate the efficacy and safety of Spiriva (thiotropium bromide 18 microg for inhalation via a HandiHaler device) in patients with chronic obstructive pulmonary disease (COPD) of all severities in routine clinical practice in Russia.

Subjects And Methods: The study enrolled 407 patients (68 women and 339 men) with COPD who used thiotropium bromide (Spiriva) for 8 weeks. Most (72.